CA2363503A1 - Procedes de diagnostic et de therapie des maladies des yeux associees aux drusen - Google Patents

Procedes de diagnostic et de therapie des maladies des yeux associees aux drusen Download PDF

Info

Publication number
CA2363503A1
CA2363503A1 CA002363503A CA2363503A CA2363503A1 CA 2363503 A1 CA2363503 A1 CA 2363503A1 CA 002363503 A CA002363503 A CA 002363503A CA 2363503 A CA2363503 A CA 2363503A CA 2363503 A1 CA2363503 A1 CA 2363503A1
Authority
CA
Canada
Prior art keywords
therapeutics
diagnostics
ocular disorders
associated ocular
drusen associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002363503A
Other languages
English (en)
Other versions
CA2363503C (fr
Inventor
Gregory S. Hageman
Robert F. Mullins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation UIRF
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2363503A1 publication Critical patent/CA2363503A1/fr
Application granted granted Critical
Publication of CA2363503C publication Critical patent/CA2363503C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002363503A 1999-03-05 2000-03-06 Procedes de diagnostic et de therapie des maladies des yeux associees aux drusen Expired - Fee Related CA2363503C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12305299P 1999-03-05 1999-03-05
US60/123,052 1999-03-05
US51023000A 2000-02-22 2000-02-22
US09/510,230 2000-02-22
PCT/US2000/005858 WO2000052479A2 (fr) 1999-03-05 2000-03-06 Procedes de diagnostic et de therapie des maladies des yeux associees aux drusen

Publications (2)

Publication Number Publication Date
CA2363503A1 true CA2363503A1 (fr) 2000-09-08
CA2363503C CA2363503C (fr) 2009-03-10

Family

ID=26821176

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002363503A Expired - Fee Related CA2363503C (fr) 1999-03-05 2000-03-06 Procedes de diagnostic et de therapie des maladies des yeux associees aux drusen

Country Status (4)

Country Link
EP (1) EP1161686A2 (fr)
AU (1) AU3395800A (fr)
CA (1) CA2363503C (fr)
WO (1) WO2000052479A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114592B2 (en) 2008-03-18 2012-02-14 Cambridge Enterprise Limited Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275782A1 (en) 1999-04-20 2006-12-07 Illumina, Inc. Detection of nucleic acid reactions on bead arrays
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
DE60136272D1 (de) 2000-04-29 2008-12-04 Univ Iowa Res Found Diagnostika und therapeutika für makula degeneration erkrankungen
US7470659B2 (en) 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
US6986995B2 (en) * 2002-02-28 2006-01-17 Prometheus Laboratories, Inc. Methods of diagnosing liver fibrosis
CN103920142A (zh) 2005-02-14 2014-07-16 爱荷华大学研究基金会 治疗和诊断年龄相关性黄斑变性的方法和试剂
US8088773B2 (en) * 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods
CA2621953A1 (fr) * 2005-09-09 2007-03-22 University Of Iowa Research Foundation Marqueurs biologiques associes a la degenerescence maculaire liee a l'age
CN104768533A (zh) 2012-06-11 2015-07-08 马库克利尔公司 治疗性制剂和治疗方法
GB201306627D0 (en) * 2013-04-11 2013-05-29 Thompson Richard Marker
US9248162B2 (en) 2013-03-14 2016-02-02 Baxalta Incorporated Factor H for treatment of rheumatoid arthritis
SI2968457T1 (sl) 2013-03-14 2018-11-30 Baxalta Incorporated Faktor H za transplantacijo
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
US9423394B2 (en) * 2013-12-13 2016-08-23 TheraOptix, Inc. Retinal pigment epithelial primary cell culture system producing subcellular deposits
US11253614B2 (en) 2016-08-23 2022-02-22 University Of Maryland, Baltimore Methods for detecting and/or predicting age-related macular degeneration and/or Alzheimer's disease
US20220128573A1 (en) * 2019-02-13 2022-04-28 Narayana Nethralaya Foundation Biomarkers for diagnosis of ocular diseases and the method thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114592B2 (en) 2008-03-18 2012-02-14 Cambridge Enterprise Limited Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof

Also Published As

Publication number Publication date
WO2000052479A3 (fr) 2001-02-01
CA2363503C (fr) 2009-03-10
AU3395800A (en) 2000-09-21
EP1161686A2 (fr) 2001-12-12
WO2000052479A2 (fr) 2000-09-08

Similar Documents

Publication Publication Date Title
CA2407715A1 (fr) Diagnostic et therapeutique pour des troubles lies a une degenerescence maculaire
CA2363503A1 (fr) Procedes de diagnostic et de therapie des maladies des yeux associees aux drusen
AU2002366641A1 (en) Methods for inhibiting ocular processes
HK1040266A1 (en) Titanium alloy and method for producing the same.
ZA200108530B (en) 4,5,6,7-tetrahydroindazole derivatives as antitumor agents.
CA2332521A1 (fr) Composition pharmaceutique destinee a traiter ou prevenir les troubles du sommeil
TR199501517A2 (tr) Yeni antitrombotik formül, bunun imal edilmesi icin proses, ve bunun kullanilmasi.
HK1038007A1 (en) Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline.
WO2001058476A3 (fr) Procedes et compositions pour le traitement de la maladie d'alzheimer par le renforcement de l'activite de la plasmine ou de l'activite du type de la plasmine
WO2001016377A3 (fr) Diagnostic et therapie de l'osteoporose
AU3824599A (en) Method for producing (s,s)-benzyl-2,8-diazabicyclo{4.3.0}nonane
CA2347863A1 (fr) Traitement des affections de la retine
ZA993852B (en) Diaza-Spiro (3,5)nonane derivates.
CA2384433A1 (fr) Nouveaux derives d'acide betulinique presentant une activite antiangiogenese, procedes de production de ces derives et leur utilisation pour traiter une tumeur associee a l'angiogenese
ZA997027B (en) High-temperature, water-based lubricant and process for making the same.
ZA200002941B (en) Process for the preparation of butanediol, butyrolactone and tetrahydrofuran.
CY2362B1 (en) Use of 1-hydroxy-2-pyridone for the treatment of seborrheic dermatitis.
ZA99569B (en) 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3 hydroxyamic acids.
CA2369825A1 (fr) Composants microstructures
EP1019092A4 (fr) Outils therapeutiques et diagnostiques pour desordres lies a une mauvaise tolerance glucidique
WO1999051779A3 (fr) Traitement et diagnostic du glaucome
HK1038510A1 (en) Use of neurotrophic factor stimulators for the treamtent of ophthalmic neurodegenerative diseases.
ZA966749B (en) Endoparasiticidal compositions based on didepsipeptides, new didepsipeptides and processes for their preparation.
MX9603516A (es) Derivados de oxima y su uso como pesticidas.
ZA966347B (en) Process for the preparation of 1,4-butenediol.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180306